Dexamethasone 0.4 mg · intracanalicular insert
Steroid, Injections & Implants
Approved uses
Ocular inflammation and pain following ophthalmic surgery
One insert placed in the lower lacrimal punctum, releasing 0.4 mg dexamethasone over up to 30 days
No drop schedule and no patient adherence problem; it resorbs on its own
Ocular itching associated with allergic conjunctivitis, age 2 and over
One insert placed in the lower lacrimal punctum, releasing 0.4 mg dexamethasone over up to 30 days
Contraindications
- Active corneal, conjunctival or canalicular infection, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella
- Mycobacterial infection
- Fungal disease of the eye
- Dacryocystitis
0.4 mg dexamethasone insert, packs of 10 inserts or 1 insert
Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.
Warnings & Precautions
- Intraocular pressure increase: prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Use steroids with caution in the presence of glaucoma, and monitor intraocular pressure during treatment.
- Bacterial infection: corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.
- Viral infections: ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).
- Fungal infections: consider fungus invasion in any persistent corneal ulceration where a steroid has been used or is in use, and take a fungal culture when appropriate.
- Delayed healing: the use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
- Other potential corticosteroid complications: a physician should make the initial prescription and any renewal only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. Re-evaluate the patient if signs and symptoms fail to improve after 2 days.
Common Side Effects
The most commonly reported adverse reactions were anterior chamber inflammation and elevations in intraocular pressure.
Pregnancy: No adequate or well-controlled studies with DEXTENZA in pregnant women. Topical ocular dexamethasone given to pregnant mice and rabbits during organogenesis produced embryofetal lethality, cleft palate and multiple visceral malformations.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth and interfere with endogenous corticosteroid production, but the systemic concentration of dexamethasone after DEXTENZA is low. There is no information on the presence of DEXTENZA in human milk, its effects on the breastfed infant, or its effects on milk production.
The safety and effectiveness of DEXTENZA for the treatment of ocular inflammation and pain following ophthalmic surgery have been established in pediatric patients. Safety and effectiveness for ocular itching associated with allergic conjunctivitis have been established in pediatric patients aged 2 years and older. DEXTENZA is not recommended for ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure. A similar safety profile was observed between pediatric and adult patients.